STING激动剂c-di-AMP作为佐剂优于poly(I:C)/CpG配方:皮下接种可溶性蛋白抗原或DEC-205靶向树突状细胞抗原的比较研究
该研究在C57BL/6小鼠中直接比较STING激动剂c-di-AMP与Toll样受体配体配方poly(I:C)/CpG的佐剂效果,采用模型抗原卵清蛋白(OVA)进行皮下接种,包括可溶性蛋白和αDEC-OVA靶向树突状细胞(DC)两种方式。结果显示,c-di-AMP诱导的抗原特异性IgG抗体水平显著高于poly(I:C)/CpG;在可溶性OVA接种中,c-di-AMP还显著增强CTL、Th1和产IFNγ的CD8+记忆T细胞应答;在DC靶向接种中,c-di-AMP显著增加Th1和Th2细胞应答,且仅c-di-AMP组Th1应答占主导。
要点
- c-di-AMP佐剂诱导的抗原特异性IgG水平显著高于poly(I:C)/CpG。
- 可溶性OVA接种中c-di-AMP增强CTL、Th1和CD8+记忆T细胞应答。
- DC靶向接种中c-di-AMP诱导更强Th1/Th2应答且Th1占主导。
核心结论
- c-di-AMP在皮下接种可溶性抗原及DC靶向抗原时均表现出优于poly(I:C)/CpG的佐剂特性。
研究设计与样本
- 在C57BL/6小鼠中比较c-di-AMP与poly(I:C)/CpG佐剂,使用模型抗原OVA进行皮下接种,包括可溶性蛋白和αDEC-OVA靶向DC两种方式。
主要发现
- 可溶性OVA接种中,c-di-AMP组抗原特异性IgG水平显著高于poly(I:C)/CpG组。
- 可溶性OVA接种中,c-di-AMP诱导的CTL、Th1和产IFNγ的CD8+记忆T细胞应答显著强于poly(I:C)/CpG。
- DC靶向接种中,c-di-AMP组Th1和Th2细胞应答显著高于poly(I:C)/CpG组。
- DC靶向接种中,仅c-di-AMP组Th1应答占总体T细胞应答的主导。
临床怎么用
- 提示c-di-AMP可作为候选佐剂用于皮下疫苗开发,尤其适用于DC靶向策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the most efficient strategy to protect from infectious diseases and the induction of a protective immune response not only depends on the nature of the antigen, but is also influenced by the vaccination strategy and the co-administration of adjuvants. Therefore, the precise monitoring of adjuvant candidates and their immune modulatory properties is a crucial step in vaccine development. Here, one central aspect is the induction of appropriate humoral and cellular effector mechanisms. In our study we performed a direct comparison of two promising candidates in adjuvant development, the STING activator bis-(3,5)-cyclic dimeric adenosine monophosphate (c-di-AMP) and the Toll-like receptor ligand formulation poly(I:C)/CpG. These were evaluated in C57BL/6 mice using the model antigen ovalbumin (OVA) in subcutaneous vaccination with soluble protein as well as in a dendritic cell (DC) targeting approach (αDEC-OVA). Strikingly, c-di-AMP as compared to poly(I:C)/CpG resulted in significantly higher antigen-specific IgG antibody levels when used in immunization with soluble OVA as well as in antigen targeting to DC. In vaccination with soluble OVA, c-di-AMP induced a significantly stronger CTL, Th1 and IFNγ-producing CD8+ memory T cell response than poly(I:C)/CpG. The response was CTL and Th1 cell dominated, a profile shared by both adjuvants. In the context of targeting OVA to DC, c-di-AMP induced significantly increased Th1 and Th2 cell responses as compared to poly(I:C)/CpG. Interestingly, the Th1 response dominated the overall T cell response only when c-di-AMP was used, indicating a distinct modulatory property of c-di-AMP when the DC targeting immunization approach was exploited. Taken together, we describe superior properties of c-di-AMP as compared to poly(I:C)/CpG in subcutaneous vaccination with soluble antigen as well as antigen targeting to DC. This indicates exceptionally effective adjuvant properties for c-di-AMP and provides compelling evidence of its potential for further adjuvant development, especially also when using DC targeting approaches.
引用
- Volckmar J, Knop L, Stegemann-Koniszewski S, et al. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells. Vaccine. 2019. PMID: 31320219. doi:10.1016/j.vaccine.2019.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。